Latest news - Novo Nordisk
Dec 15, 2024 · We plan to invest 2.9 billion Danish kroner to establish a cutting-edge quality control laboratory in Hillerød, Denmark. Environmental challenges have never been more critical or more urgent than they are today. But at Novo Nordisk, we never allow complexity to become a barrier to change.
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and …
Dec 20, 2024 · Bad news for Novo Nordisk (NVO-0.32%) Friday was good news for Eli Lilly (LLY-1.38%) and Viking Therapeutics (VKTX-3.56%), its two main rivals in the field of weight loss drugs.This morning, Novo ...
Novo Nordisk shares plunge on the back of disappointing
5 days ago · Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall wiped out €90bn in market valuation on Friday.
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Novo Nordisk A/S: CagriSema demonstrates superior weight
Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and ...
Novo Holdings’ purchase of Catalent set to close after regulators ...
Dec 16, 2024 · Novo Holdings owns about one-quarter of Novo Nordisk shares, but controls roughly 77% of the company’s voting capital. Novo Holdings itself is wholly owned by the Novo Nordisk Foundation. In its statement on the deal close, Novo Nordisk said the acquisition of the three Catalent sites will have a mid single-digit negative impact on operating ...
Novo Nordisk Shares Plunge After New Obesity Shot Disappoints
Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker’s stock-market value.
News Details - novonordisk.com
Oct 21, 2024 · Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial.
Company announcements & press releases - Novo Nordisk
Be the first to read our company announcements and press releases. Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page.
Novo Nordisk shares tumble as data on weight-loss drug trial …
Dec 20, 2024 · Novo Nordisk and Eli Lilly are competing for dominance in a market that grew sevenfold in just three years to $24bn in 2023, according to data analytics firm Iqvia.